Clinical Impact of DESTINY-Breast09 in HER2+ Breast Cancer Management
Key Points
-
DESTINY-Breast09 demonstrates a clinically meaningful improvement in outcomes for patients with HER2-positive metastatic breast cancer in the first-line setting.
-
Trastuzumab deruxtecan (T-DXd) plus pertuzumab was superior to the standard regimen of a taxane plus trastuzumab and pertuzumab.
-
Sequencing of antibody-drug conjugates (ADCs) is becoming increasingly important.
The phase 3 DESTINY-Breast09 clinical trial showed that first-line treatment with T-DXd plus pertuzumab extends progression-free survival by more than a year in patients with HER2-positive advanced or metastatic breast cancer compared with the standard of care regimen that includes a taxane plus trastuzumab and pertuzumab.
At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Hope Rugo, MD, FASCO, of City of Hope Comprehensive Cancer Center, and Arya Mariam Roy, MD, of The Ohio State University Comprehensive Cancer Center, offered an analysis on DESTINY-Breast09 and its impact in the clinical setting.
Furthermore, Dr. Rugo discussed the growing importance of ADC sequencing as more ADCs, such as T-DXd, gain FDA approval. She shared how patient-reported outcomes and long-term activity of the agent will help put the treatment into practice.